What is Sutro Biopharma's change in accrued liabilities?

Sutro Biopharma (STRO) reported change in accrued liabilities of -$9.29M in Q1 2026.

How has Sutro Biopharma's change in accrued liabilities changed year-over-year?

Sutro Biopharma's change in accrued liabilities decreased by 587.5% year-over-year, from -$1.35M to -$9.29M.

What does change in accrued liabilities mean?

Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.

Sutro Biopharma STRO Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Gilead SciencesGILD

-$702M-188%

RegenxbioRGNX

-$16.73M-15.5%

Nuvectis Pharma, Inc.NVCT

-$79K-416%

XencorXNCR

-$707K+77.6%

SchrodingerSDGR

-$14.49M+29.7%

Roivant SciencesROIV

$63.23M—

Other financials

Income statement

See full

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

See full

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

See full

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

See full

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

See full

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

See full

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sutro Biopharma's change in accrued liabilities?: Sutro Biopharma (STRO) reported change in accrued liabilities of -$9.29M in Q1 2026.
How has Sutro Biopharma's change in accrued liabilities changed year-over-year?: Sutro Biopharma's change in accrued liabilities decreased by 587.5% year-over-year, from -$1.35M to -$9.29M.
What does change in accrued liabilities mean?: Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.